Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0JT5I
|
|||
Former ID |
DIB018024
|
|||
Drug Name |
PF-04457845
|
|||
Synonyms |
PF-04457845; 1020315-31-4; UNII-H4C81M8YYW; H4C81M8YYW; CHEMBL1651534; PF 04457845; PF04457845; C23H20F3N5O2; N-pyridazin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; N-Pyridazin-3-yl-4-((3-(5-(trifluoromethyl)pyridin-2-yl)oxyphenyl)methylidene)piperidine-1-carboxamide; 1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-;1-Piperidinecarboxamide, N-3-pyridazinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methylene]-
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Liver disease [ICD-11: DB90-BD99] | Phase 2 | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C23H20F3N5O2
|
|||
Canonical SMILES |
C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4
|
|||
InChI |
1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32)
|
|||
InChIKey |
BATCTBJIJJEPHM-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1020315-31-4
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [2] |
BioCyc | Anandamide degradation | |||
KEGG Pathway | Retrograde endocannabinoid signaling | |||
Panther Pathway | Anandamide degradation |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6694). | |||
REF 2 | Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.